6533b7dbfe1ef96bd1270a97
RESEARCH PRODUCT
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study
Flavio CaprioliElena MossoMaria CappelloGiovanni MaconiElisa GremeseGiammarco MocciMarco DapernoStefano FestaEdoardo SavarinoAnna TestaAlessandro ArmuzziGionata FiorinoG. LainoSilvia MazzuoliStefano AliverniniAlessandro SartiniDaniela PuglieseLucio SarpiGiorgia BodiniLivia BianconeAlessandra D'amoresubject
MaleCrohn’s diseaseSettore MED/16 - REUMATOLOGIAPsoriaticCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Hepatology; GastroenterologyInflammatory bowel disease0302 clinical medicineClinical endpointCrohn's disease Psoriasis Psoriatic arthritis Ulcerative colitis UstekinumabCrohn's diseaseSettore MED/12 - GastroenterologiaGastroenterologyMiddle AgedUlcerative colitisCrohn's diseaseTreatment OutcomeItaly030220 oncology & carcinogenesisPsoriatic arthritis030211 gastroenterology & hepatologyFemaleUstekinumabmedicine.drugAdultmedicine.medical_specialty03 medical and health sciencesPsoriatic arthritisCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Adult; Aged; Arthritis Psoriatic; Dermatologic Agents; Female; Humans; Inflammatory Bowel Diseases; Italy; Logistic Models; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young AdultYoung AdultInternal medicinePsoriasisUstekinumabmedicineHumansPsoriasisAgedRetrospective StudiesHepatologybusiness.industryArthritisArthritis Psoriaticmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesCrohn’s disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; UstekinumabLogistic ModelsUlcerative colitisConcomitantDermatologic Agentsbusinessdescription
Abstract Background Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results Seventy patients (64 Crohn’s disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4–67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9–23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event. Conclusions Subcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-01 |